These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Chang JT; Staffa JA; Parks M; Green L Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925 [TBL] [Abstract][Full Text] [Related]
26. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. McKenney JM; Davidson MH; Jacobson TA; Guyton JR; Am J Cardiol; 2006 Apr; 97(8A):89C-94C. PubMed ID: 16581336 [TBL] [Abstract][Full Text] [Related]
27. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins. Barter PJ; Rye KA Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953 [No Abstract] [Full Text] [Related]
28. Intensive lipid-lowering therapy: obvious benefits, possible risks. Zimlichman E; Szyper-Kravitz M; Katz U; Shoenfeld Y Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117 [No Abstract] [Full Text] [Related]
29. Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease. Gotto AM Circulation; 2006 Sep; 114(12):1310-4; discussion 1314. PubMed ID: 16982952 [No Abstract] [Full Text] [Related]
30. Issues that led to the withdrawal of cerivastatin. Black DM Curr Atheroscler Rep; 2003 Jan; 5(1):10. PubMed ID: 12562534 [No Abstract] [Full Text] [Related]
31. Complications and side effects. Concerns about statins. TreatmentUpdate; 2005; 17(4):5-6. PubMed ID: 17228472 [No Abstract] [Full Text] [Related]
32. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Kashani A; Phillips CO; Foody JM; Wang Y; Mangalmurti S; Ko DT; Krumholz HM Circulation; 2006 Dec; 114(25):2788-97. PubMed ID: 17159064 [TBL] [Abstract][Full Text] [Related]
33. On the mechanisms of statin-induced myopathy. Laaksonen R Clin Pharmacol Ther; 2006 Jun; 79(6):529-31. PubMed ID: 16765140 [No Abstract] [Full Text] [Related]
34. [Statin-induced Parkinson's-syndrome. Reader's letter on the article by J. Finsterer in "Der Nervenarzt" (2003) 74:115-122]. Müller T Nervenarzt; 2003 Aug; 74(8):726-7. PubMed ID: 12904874 [No Abstract] [Full Text] [Related]
35. Myopathy caused by a combination rosuvastatin and fenofibrate. Dedhia V; Munsi SC J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748 [No Abstract] [Full Text] [Related]
36. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen. Marsà Carretero M; Alos Manrique C; Valles Callol JA Br J Gen Pract; 2002 Mar; 52(476):235-6. PubMed ID: 12030671 [No Abstract] [Full Text] [Related]
37. Succinylcholine should be avoided in patients on statin therapy. Lee C Anesthesiology; 2011 Jul; 115(1):6-7. PubMed ID: 21587061 [No Abstract] [Full Text] [Related]
38. Differential association between statin exposure and elevated levels of creatine kinase. Chan J; Hui RL; Levin E Ann Pharmacother; 2005 Oct; 39(10):1611-6. PubMed ID: 16160000 [TBL] [Abstract][Full Text] [Related]
39. [Statins in practice of the vascular surgeon and cardiologist]. Pokrovskiĭ AV; Suntsov DS Angiol Sosud Khir; 2009; 15(2):123-7. PubMed ID: 19806952 [TBL] [Abstract][Full Text] [Related]
40. [Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence]. SantaCruz PL; González A; León ME; Fernández MY Nefrologia; 2002; 22(3):301-2. PubMed ID: 12123135 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]